首页> 外文期刊>Experimental Eye Research >Blockade of CCR7 leads to decreased dendritic cell migration to draining lymph nodes and promotes graft survival in low-risk corneal transplantation
【24h】

Blockade of CCR7 leads to decreased dendritic cell migration to draining lymph nodes and promotes graft survival in low-risk corneal transplantation

机译:在低风险角膜移植中,CCR7的阻断导致树突状细胞向淋巴结转移的迁移减少,并促进移植物存活

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The chemokine receptor CCR7 is essential for migration of mature dendritic cells (DCs) to the regional lymph nodes, and it has been shown that blocking of CCR7 improves graft survival after high-risk corneal transplantation in vascularized recipient corneas. However, it is so far unknown whether blocking of CCR7 reduces migration of DCs from the avascular cornea to the draining lymph nodes and whether this leads to improved graft survival also in the low-risk setting of corneal transplantation, which accounts for the majority of perforating transplantations performed. Therefore, in this study, pellets containing Freund's adjuvant and bovine serum albumin (BSA) conjugated to Alexa488 fluorescent dye were implanted into the corneal stroma of BALB/c mice to analyze antigen uptake by corneal DCs and their migration to the regional lymph nodes. After pellet implantation, mice were either treated by local administration of a CCR7 blocking fusion protein that consisted of CCL19 fused to the Fc part of human IgG1 or a control-IgG. In vivo fluorescence microscopy showed uptake of Alexa488-conjugated BSA by corneal DCs within 8 h. Furthermore, analysis of single cell suspensions of draining lymph nodes prepared after 48 h revealed that 2.1 +/- 0.3% of CD11c(+) cells were also Alexa488(+). Importantly, DC migration was significantly reduced after topical administration of CCL19-IgG (1.2 +/- 0.2%; p < 0.05). To test the effect of CCR7 blockade on graft rejection after allogeneic low-risk keratoplasty, corneal transplantations were performed using C57BL/6-mice as donors and BALB/c-mice as recipients. Treatment mice received two intraperitoneal loading doses of CCL19-IgG prior to transplantation, followed by local treatment with CCL19-IgG containing eye drops for the first two weeks after transplantation. Control mice received same amounts of control-IgG. Kaplan-Meier survival analysis showed that in the CCL19-IgG treated group, 76% of the grafts survived through the end of the 8 week observation period, whereas 38% of the grafts survived in the control group (p < 0.05). Taken together, our study shows that blockade of CCR7 reduces the migration of mature corneal DCs to the draining lymph nodes and leads to improved graft survival in low-risk corneal transplantation. (C) 2015 Elsevier Ltd. All rights reserved.
机译:趋化因子受体CCR7对于成熟树突状细胞(DC)迁移至区域淋巴结至关重要,并且已显示,在高风险角膜移植后,血管化受体角膜中的CCR7阻断可改善移植物存活。然而,到目前为止,尚不清楚CCR7的阻滞是否能减少DC从无血管角膜向引流淋巴结的迁移,以及在低风险的角膜移植中是否也能改善移植物的存活率,这是造成穿孔最多的原因进行了移植。因此,在这项研究中,将包含弗氏佐剂和与Alexa488荧光染料缀合的牛血清白蛋白(BSA)的沉淀物植入BALB / c小鼠的角膜基质中,以分析角膜DC吸收抗原及其向区域淋巴结的迁移。颗粒植入后,通过局部施用CCR7阻断融合蛋白(包括与人IgG1 Fc部分或对照IgG融合的CCL19组成)来治疗小鼠。体内荧光显微镜检查显示,角膜DC在8小时内吸收了Alexa488共轭BSA。此外,对48小时后准备的引流淋巴结的单细胞悬浮液的分析表明,2.1 +/- 0.3%的CD11c(+)细胞也是Alexa488(+)。重要的是,局部施用CCL19-IgG后,DC迁移明显减少(1.2 +/- 0.2%; p <0.05)。为了测试同种异体低风险角膜移植术后CCR7阻断对移植排斥的影响,以C57BL / 6-小鼠为供体,BALB / c-小鼠为受体,进行了角膜移植。治疗小鼠在移植前接受两次腹膜内负荷剂量的CCL19-IgG,然后在移植后的前两周用含CCL19-IgG的眼药水局部治疗。对照小鼠接受相同量的对照IgG。 Kaplan-Meier存活分析表明,在CCL19-IgG处理组中,到8周观察期结束时,有76%的移植物存活,而在对照组中,有38%的移植物存活(p <0.05)。综上所述,我们的研究表明,CCR7的阻断减少了成熟角膜DC向引流淋巴结的迁移,并提高了低风险角膜移植的移植物存活率。 (C)2015 Elsevier Ltd.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号